New drug KMY tablets enter first human safety tests
NCT ID NCT07314541
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial will test the safety and tolerability of KMY tablets in 120 healthy adults aged 18 to 45. Participants will receive either the drug or a placebo, and researchers will monitor for side effects and how the drug moves through the body. The study also looks at how food affects drug absorption. Since this is a first-in-human trial, there is no direct treatment benefit for volunteers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- KMY Tablets
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Suzhou Municipal Hospital
Suzhou, Jiangsu, 215000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults